The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Eric Van Cutsem; R. Mayer; Stéphanie Laurent; Robert Winkler; Cristina Grávalos; Manuel Benavides; Federico Longo-Muñoz; Fabienne Portales; Fortunato Ciardiello; Salvatore Siena; Kensei Yamaguchi; Kei Muro; Tadamichi Denda; Yasushi Tsuji; Lukas Makris; Patrick J. Loehrer; Heinz‐Josef Lenz; Atsushi Ohtsu

doi:10.1016/j.ejca.2017.10.009

Abstract

Trifluridine/tipiracil was effective in all subgroups, regardless of age, geographical origin or KRAS status. This trial is registered with ClinicalTrials.gov: NCT01607957.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cutsem et al. (2017) studied this question.

synapsesocial.com/papers/69dabb094a1e15904c835f26 https://doi.org/10.1016/j.ejca.2017.10.009

View Full Paper

Ask AI

Bookmark

Share

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Abstract

Discussion

Cite This Study

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading